bioAffinity Technologies (BIAF) to Announce Quarterly Earnings on Wednesday

bioAffinity Technologies (NASDAQ:BIAF) will likely be issuing its Q2 2026 results before the market opens on Wednesday, August 19th. Analysts expect the company to announce earnings of ($2.10) per share and revenue of $1.7010 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

bioAffinity Technologies (NASDAQ:BIAF) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $1.46. The firm had revenue of $1.51 million during the quarter, compared to analysts’ expectations of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 196.80%.

bioAffinity Technologies Trading Down 0.8%

NASDAQ:BIAF opened at $0.49 on Wednesday. bioAffinity Technologies has a one year low of $0.46 and a one year high of $13.50. The company has a market cap of $2.30 million, a PE ratio of -0.07 and a beta of -1.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.36 and a quick ratio of 1.34. The firm has a 50-day moving average of $0.88 and a 200-day moving average of $1.63.

Analyst Ratings Changes

A number of analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. Wall Street Zen raised bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Trading of bioAffinity Technologies

An institutional investor recently bought a new stake in bioAffinity Technologies stock. Scientech Research LLC acquired a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned about 0.46% of bioAffinity Technologies at the end of the most recent quarter. 1.64% of the stock is owned by institutional investors and hedge funds.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.